EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU
WATERTOWN, Mass. and NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing
innovative ophthalmic products, and Vision Center Network of America, LLC (“VCNA”), a Clinically Integrated Network (“CIN”) with the aim of significantly improving the healthcare delivery system in
the specialty area of ophthalmic surgery, today announced that they have entered into an purchase agreement for DEXYCU (dexamethasone intraocular suspension) 9% for its network of nine surgery
centers located in New York and New Jersey that perform an estimated 60,000 cataract procedures annually. The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical
protocols for treating ocular inflammation associated with cataract surgery.
Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals stated, “We look forward to working with VCNA to further broaden DEXYCU’s commercial reach in the United States and to improve the care for patients by providing an effective therapy for treating inflammation associated with cataract surgery. VCNA is a fast-growing network and we look forward to being their preferred partner.”
Dr. Jerome Levy, President and Chairman of the Board at VCNA said, “We are delighted that Eyepoint Pharmaceuticals has decided to enter into a relationship with VCNA. Given the high volume of cataract surgeries performed annually across our centers, we believe that this agreement will enhance the value proposition we offer to our patients and payers.”
About VCNA
Vision Center Network of America, LLC (“VCNA”) is comprised of nine prominent and busy ophthalmic ambulatory surgery centers that perform an estimated 60,000 cataract procedures annually. VCNA came
together in March of 2016 with the intention of advancing Value-Based Care (defined as high quality healthcare at a lower than average cost) for the patients they currently serve within the
Northeast United States.
Lesen Sie auch
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to
help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU, the first approved intraocular product for the treatment of postoperative
inflammation, and YUTIQ, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert
technology for extended intravitreal drug delivery including EYP-1901 targeting wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. EyePoint Pharmaceuticals is
headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.